Back to News
Market Impact: 0.12
Epitel Adds Proven Medtech Leader James Reinstein to Board As Company Enters Next Stage of Growth
Source: Business Wire
Management & GovernanceHealthcare & Biotech
Epitel appointed James Reinstein to its board as the epilepsy-focused medtech company expands its REMI® platform and enters its next growth phase. The company cited Reinstein's medical-technology and epilepsy experience, but disclosed no financial metrics, commercial milestones, or guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- FG Nexus repurchases 46% of outstanding common shares
- Indonesian Power Politics, Not Markets, Forced Out Finance Chief
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Document Search Enhancements, AI Enhancements, AI Actions, & Chat Export
- AI Vendor Landscape for Institutional Investment Teams